| First Author | Yamashita A | Year | 2014 |
| Journal | Nature | Volume | 513 |
| Issue | 7519 | Pages | 507-11 |
| PubMed ID | 25231866 | Mgi Jnum | J:217305 |
| Mgi Id | MGI:5613736 | Doi | 10.1038/nature13775 |
| Citation | Yamashita A, et al. (2014) Statin treatment rescues FGFR3 skeletal dysplasia phenotypes. Nature 513(7519):507-11 |
| abstractText | Gain-of-function mutations in the fibroblast growth factor receptor 3 gene (FGFR3) result in skeletal dysplasias, such as thanatophoric dysplasia and achondroplasia (ACH). The lack of disease models using human cells has hampered the identification of a clinically effective treatment for these diseases. Here we show that statin treatment can rescue patient-specific induced pluripotent stem cell (iPSC) models and a mouse model of FGFR3 skeletal dysplasia. We converted fibroblasts from thanatophoric dysplasia type I (TD1) and ACH patients into iPSCs. The chondrogenic differentiation of TD1 iPSCs and ACH iPSCs resulted in the formation of degraded cartilage. We found that statins could correct the degraded cartilage in both chondrogenically differentiated TD1 and ACH iPSCs. Treatment of ACH model mice with statin led to a significant recovery of bone growth. These results suggest that statins could represent a medical treatment for infants and children with TD1 and ACH. |
